Niagen Bioscience, Inc. (NASDAQ:NAGE – Free Report) – Equities researchers at HC Wainwright decreased their Q2 2026 earnings per share estimates for shares of Niagen Bioscience in a research note issued to investors on Monday, May 11th. HC Wainwright analyst R. Selvaraju now expects that the company will post earnings of $0.02 per share for the quarter, down from their previous estimate of $0.04. HC Wainwright has a “Buy” rating and a $11.00 price objective on the stock. The consensus estimate for Niagen Bioscience’s current full-year earnings is $0.23 per share. HC Wainwright also issued estimates for Niagen Bioscience’s Q3 2026 earnings at $0.08 EPS, Q4 2026 earnings at $0.10 EPS, FY2026 earnings at $0.28 EPS, Q1 2027 earnings at $0.06 EPS, Q2 2027 earnings at $0.08 EPS, Q4 2027 earnings at $0.12 EPS and FY2027 earnings at $0.36 EPS.
Other research analysts have also recently issued reports about the stock. Weiss Ratings reissued a “hold (c)” rating on shares of Niagen Bioscience in a research report on Tuesday, April 21st. Wall Street Zen cut shares of Niagen Bioscience from a “buy” rating to a “hold” rating in a research report on Saturday, April 25th. Finally, Canaccord Genuity Group lowered their price target on shares of Niagen Bioscience from $13.00 to $10.00 and set a “buy” rating for the company in a research report on Tuesday, May 5th. Three analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. According to data from MarketBeat.com, Niagen Bioscience has an average rating of “Moderate Buy” and a consensus price target of $14.67.
Niagen Bioscience Stock Down 4.6%
NAGE opened at $3.98 on Tuesday. The stock has a market cap of $316.97 million, a PE ratio of 18.95 and a beta of 2.17. The business has a 50 day moving average of $4.69 and a 200-day moving average of $5.77. Niagen Bioscience has a 52 week low of $3.93 and a 52 week high of $14.69.
Niagen Bioscience (NASDAQ:NAGE – Get Free Report) last released its earnings results on Wednesday, May 6th. The company reported $0.07 EPS for the quarter, beating analysts’ consensus estimates of $0.06 by $0.01. The company had revenue of $31.47 million during the quarter. Niagen Bioscience had a return on equity of 22.68% and a net margin of 14.29%.
Institutional Trading of Niagen Bioscience
A number of institutional investors and hedge funds have recently bought and sold shares of NAGE. Vanguard Group Inc. bought a new stake in Niagen Bioscience during the 3rd quarter valued at about $37,522,000. SteelPeak Wealth LLC bought a new stake in Niagen Bioscience during the 1st quarter valued at about $14,875,000. Arrowstreet Capital Limited Partnership bought a new stake in Niagen Bioscience during the 3rd quarter valued at about $13,405,000. UBS Group AG bought a new stake in Niagen Bioscience during the 3rd quarter valued at about $11,160,000. Finally, Qube Research & Technologies Ltd bought a new stake in Niagen Bioscience during the 3rd quarter valued at about $8,175,000. 15.41% of the stock is currently owned by institutional investors.
Trending Headlines about Niagen Bioscience
Here are the key news stories impacting Niagen Bioscience this week:
- Positive Sentiment: HC Wainwright raised its Q4 2027 EPS estimate to $0.12 from $0.11, suggesting improved longer-term earnings potential while maintaining a Buy rating and $11 target.
- Neutral Sentiment: The analyst also highlighted updated estimates across 2026–2027, including FY2026 EPS of $0.28 and FY2027 EPS of $0.36, indicating continued coverage but no major change to the overall investment thesis.
- Negative Sentiment: HC Wainwright cut its near-term EPS outlook for Niagen Bioscience, lowering Q2 2026 to $0.02 from $0.04, Q3 2026 to $0.08 from $0.10, Q4 2026 to $0.10 from $0.12, Q1 2027 to $0.06 from $0.07, Q2 2027 to $0.08 from $0.09, and FY2026/FY2027 estimates to $0.28 and $0.36 from $0.33 and $0.37, respectively.
- Negative Sentiment: HC Wainwright also lowered its price target from $12 to $11, which can be read as a modestly softer valuation view despite the bullish rating.
Niagen Bioscience Company Profile
Niagen Bioscience, Inc is a global bioscience company, which engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. It is pioneering research on nicotinamide adenine dinucleotide (NAD+). The company’s patent portfolio includes Nicotinamide Riboside (NR) and other NAD+ precursors, which are commercialized as the flagship ingredient Niagen. It operates through the following segments: Consumer Products, Ingredients, and Analytical Reference Standards and Services.
Featured Stories
- Five stocks we like better than Niagen Bioscience
- Sell in May and Go Away—Starting With These 3 Stocks
- Before the Moon Base Gets Built, These 4 Companies Win
- Industrial Buybacks: Top Homebuilding Supplier Leads Buyback Increases
- 3 Stocks That Win If Inflation Surprises to the Downside
Receive News & Ratings for Niagen Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Niagen Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.
